139 related articles for article (PubMed ID: 31734054)
1. Immunohistochemical analysis of the impact of ischemic change in benign prostatic hyperplasia.
Jin Cho W; Pyo JS
Pathol Res Pract; 2020 Jan; 216(1):152694. PubMed ID: 31734054
[TBL] [Abstract][Full Text] [Related]
2. Roles of NF-κB activation in benign prostatic hyperplasia and association between NF-κB and HIF-1α.
Ko YS; Pyo JS; Cho WJ
Pathol Res Pract; 2022 Sep; 237():154021. PubMed ID: 35901596
[TBL] [Abstract][Full Text] [Related]
3. [Expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor in prostate cancer and its significance].
Wang L; Chen ZJ; Wang QT; Cao WF; Jian Y; Wang SX; Zhang BH
Zhonghua Nan Ke Xue; 2006 Jan; 12(1):57-9. PubMed ID: 16483162
[TBL] [Abstract][Full Text] [Related]
4. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue.
Lekas A; Lazaris AC; Deliveliotis C; Chrisofos M; Zoubouli C; Lapas D; Papathomas T; Fokitis I; Nakopoulou L
Anticancer Res; 2006; 26(4B):2989-93. PubMed ID: 16886625
[TBL] [Abstract][Full Text] [Related]
5. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue.
Du Z; Fujiyama C; Chen Y; Masaki Z
Chin Med J (Engl); 2003 Dec; 116(12):1936-9. PubMed ID: 14687488
[TBL] [Abstract][Full Text] [Related]
6. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.
Lekas AG; Lazaris AC; Chrisofos M; Papatsoris AG; Lappas D; Patsouris E; Deliveliotis C
Urology; 2006 Aug; 68(2):436-41. PubMed ID: 16904480
[TBL] [Abstract][Full Text] [Related]
7. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia.
Wu F; Ding S; Li X; Wang H; Liu S; Wu H; Bi D; Ding K; Lu J
Oncotarget; 2016 Mar; 7(11):12053-62. PubMed ID: 26919249
[TBL] [Abstract][Full Text] [Related]
9. Potential ameliorative effects of epigallocatechin‑3‑gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats.
Zhou J; Lei Y; Chen J; Zhou X
Int Immunopharmacol; 2018 Nov; 64():162-169. PubMed ID: 30179845
[TBL] [Abstract][Full Text] [Related]
10. The effects of ROS in prostatic stromal cells under hypoxic environment.
Ren H; Li X; Cheng G; Li N; Hou Z; Suo J; Wang J; Za X
Aging Male; 2015 Jun; 18(2):84-8. PubMed ID: 25746207
[TBL] [Abstract][Full Text] [Related]
11. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
12. Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining.
Ma D; Yang B; Zhou Z; Pan D; Zhang X
Chin Med J (Engl); 2014; 127(23):4031-5. PubMed ID: 25430444
[TBL] [Abstract][Full Text] [Related]
13. [Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications].
Gao WJ; Wang YM; Wang CH; Yang XK; Wan L; Li WP
Zhonghua Nan Ke Xue; 2013 Apr; 19(4):315-20. PubMed ID: 23678709
[TBL] [Abstract][Full Text] [Related]
14. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
15. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
Monsef N; Helczynski L; Lundwall A; Påhlman S;
Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
[TBL] [Abstract][Full Text] [Related]
16. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of estrogen receptors in prostate and clinical correlation in men with benign prostatic hyperplasia.
Gangkak G; Bhattar R; Mittal A; Yadav SS; Tomar V; Yadav A; Mehta J
Investig Clin Urol; 2017 Mar; 58(2):117-126. PubMed ID: 28261681
[TBL] [Abstract][Full Text] [Related]
18. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
Boddy JL; Fox SB; Han C; Campo L; Turley H; Kanga S; Malone PR; Harris AL
Clin Cancer Res; 2005 Nov; 11(21):7658-63. PubMed ID: 16278385
[TBL] [Abstract][Full Text] [Related]
19. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
Elshal AM; Elmansy HM; Elhilali MM
BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
